期刊文献+

外周血淋巴细胞绝对值和单核细胞绝对值的比值对胃癌患者预后的预测价值 被引量:11

Effect of peripheral blood lymphocyte-to-monocyte ratio on the prognosis of gastric cancer patients
下载PDF
导出
摘要 目的探讨外周血淋巴细胞绝对值(ALC)与单核细胞绝对值(AMC)的比值(LMR)对胃癌患者预后的预测价值。方法选择接受胃癌根治术治疗的110例胃癌患者,采用Cox比例风险回归模型对可能影响患者预后的因素进行单因素及多因素分析。通过受试者工作特征(ROC)曲线确定术前外周血ALC、AMC、LMR预测胃癌患者总生存期的最佳临界值,根据LMR最佳临界值将患者分为低LMR组和高LMR组,比较两组患者的5年生存率和5年无病生存率。结果ROC曲线分析结果显示,ALC和AMC预测胃癌患者总生存期的最佳临界值分别为1.73×109/L[曲线下面积(AUC)为0.661,P﹤0.01]和0.63×109/L(AUC为0.605,P﹤0.05),LMR预测胃癌患者总生存期的最佳临界值为3.9(AUC为0.870,P﹤0.01)。Cox比例风险回归分析结果显示,TNM分期和LMR均是胃癌患者预后的独立影响因素(P﹤0.01)。高LMR组和低LMR组胃癌患者的5年生存率分别为51.2%和18.5%,差异有统计学意义(P﹤0.05);高LMR组和低LMR组胃癌患者的5年无病生存率分别为42.6%和16.2%,差异有统计学意义(P﹤0.05)。结论LMR对胃癌患者的预后评估具有一定的指导意义,可作为胃癌患者预后预测的指标。 Objective To investigate the prognostic significance of absolute lymphocyte count(ALC)to absolute monocyte count(AMC)ratio(lymphocyte-to-monocyte ratio,LMR)in patients with gastric cancer.Method 110 patients with gastric cancer who underwent radical gastrectomy were selected.Cox proportional hazard regression model was used to analyze the factors that may affect the prognosis of patients.Preoperative ALC,AMC and LMR in peripheral blood were used to determine the optimal threshold for predicting the overall survival of patients with gastric cancer by receiver operating characteristic(ROC)curve.The patients were divided into the low LMR group and the high LMR group according to the optimum critical value of LMR.The 5-year survival rate and 5-year disease-free survival rate were compared between the two groups.Result The ROC curve results showed that the optimum critical values of ALC and AMC to predict the survival of gastric cancer patients were 1.73×10^9/L[area under curve(AUC)was 0.661,P<0.01]and 0.63×10^9/L(AUC was 0.605,P<0.05),and the optimum critical value of LMR was 3.9(AUC was 0.870,P<0.01).Cox proportional risk regression analysis results showed that TNM staging and LMR were independent prognostic factors in patients with gastric cancer(P<0.01).The 5-year survival rates of gastric cancer patients in the high LMR group and the low LMR group were 51.2%and 18.5%,respectively,with significant difference(P<0.05).The 5-year disease-free survival rates of gastric cancer patients in the high LMR group and the low LMR group were 42.6%and 16.2%,respectively,with significant difference(P<0.05).Conclusion The LMR has prognostic significance for gastric cancer patients.It can be used as an index for prognosis prediction of gastric cancer patients.
作者 侯杰 耿熠 赵亚宁 刘尧 汪华 闫晓红 杨乔 HOU Jie;GENG Yi;ZHAO Yaning;LIU Yao;WANG Hua;YAN Xiaohong;YANG Qiao(Department of Medical Oncology,Baoji Municipal Central Hospital,Baoji 721008,Shaanxi,China)
出处 《癌症进展》 2019年第18期2192-2195,共4页 Oncology Progress
关键词 淋巴细胞绝对值 单核细胞绝对值 LMR 胃癌 预后 absolute lymphocyte count absolute monocyte count lymphocyte-to-monocyte ratio gastric cancer prognosis
  • 相关文献

参考文献1

二级参考文献80

  • 1Pullen AM, Kappler JW, Marrack P. Tolerance to self antigensshapes the T-cell repertoire. Immunol Rev 1989; 107: 125-139[PMID: 2522084 DOI: 10.1002/Ijc.29210].
  • 2Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A,Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer.Cochrane Database Syst Rev 2010; (3): CD004064 [PMID:20238327 DOI: 10.1002/14651858.Cd004064.Pub3].
  • 3Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L,Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G,Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumabin combination with chemotherapy versus chemotherapy alone fortreatment of HER2-positive advanced gastric or gastro-oesophagealjunction cancer (ToGA): a phase 3, open-label, randomisedcontrolled trial. Lancet 2010; 376: 687-697 [PMID: 20728210DOI: 10.1016/S0140-6736(10)61121-X].
  • 4Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A,Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y, Zhu M,Tang R, Anderson A, Dubey S, Oliner KS, Loh E. Rilotumumabin combination with epirubicin, cisplatin, and capecitabine asfirst-line treatment for gastric or oesophagogastric junctionadenocarcinoma: an open-label, dose de-escalation phase 1bstudy and a double-blind, randomised phase 2 study. LancetOncol 2014; 15: 1007-1018 [PMID: 24965569 DOI: 10.1016/S1470-2045(14)70023-3].
  • 5Satoh T, Lee KH, Rha SY, Sasaki Y, Park SH, Komatsu Y, YasuiH, Kim TY, Yamaguchi K, Fuse N, Yamada Y, Ura T, Kim SY,Munakata M, Saitoh S, Nishio K, Morita S, Yamamoto E, ZhangQ, Kim JM, Kim YH, Sakata Y. Randomized phase II trial ofnimotuzumab plus irinotecan versus irinotecan alone as secondlinetherapy for patients with advanced gastric cancer. GastricCancer 2015; 18: 824-832 [PMID: 25185971 DOI: 10.1007/s10120-014-0420-9].
  • 6Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermalgrowth factor receptor family as a central element for cellularsignal transduction and diversification. Endocr Relat Cancer 2001;8: 11-31 [PMID: 11350724 DOI: 10.1677/erc.0.0080011].
  • 7Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B,Gout I, Fry MJ, Waterfield MD, Downward J. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994; 370: 527-532[PMID: 8052307 DOI: 10.1038/370527a0].
  • 8Datta SR, Brunet A, Greenberg ME. Cellular survival: a play inthree Akts. Genes Dev 1999; 13: 2905-2927 [PMID: 10579998DOI: 10.1101/gad.13.22.2905].
  • 9Kelley GG, Reks SE, Ondrako JM, Smrcka AV. PhospholipaseC(epsilon): a novel Ras effector. EMBO J 2001; 20: 743-754[PMID: 11179219 DOI: 10.1093/emboj/20.4.743].
  • 10Downward J. Targeting RAS signalling pathways in cancertherapy. Nat Rev Cancer 2003; 3: 11-22 [PMID: 12509763 DOI:10.1038/nrc969].

共引文献12

同被引文献147

引证文献11

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部